Tamsulosin Hydrochloride
Product Images NDC 10544-280

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 10544-280). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Blenheim Pharmacal, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Label Tamsulosin Hci Caps 0 4mg Bpi(10544 280 30) Activas(0228 2996 11) Rev1 Copy)

Label for Tamsulosin Hydrochloride Capsules, USP 0.4 mg, containing 30 capsules. The label includes storage instructions, manufacturer information (Blenheim Pharmacal, Inc.), and package details. Product NDC is 10544-280-30 with manufacturer code 0228-2996-11.*

FDA Label Image

Ab8b786d-figure-01 (Ab8b786d Figure 01)

Chemical structure of Tamsulosin hydrochloride, showing the molecular arrangement including methoxy and ethoxy functional groups along with the hydrochloride salt indicated.*

FDA Label Image

Ab8b786d-figure-02 (Ab8b786d Figure 02)

A pharmacokinetic curve chart comparing plasma concentration (ng/mL) of Tamsulosin hydrochloride over time (hours) under fasting and fed conditions. The graph shows two lines, dashed for fasting and solid for fed, illustrating different plasma concentration profiles up to 36 hours.*

FDA Label Image

Ab8b786d-figure-03 (Ab8b786d Figure 03)

A line graph depicting mean change over duration of treatment in weeks comparing three groups: placebo, 0.4 mg, and 0.8 mg dosages. The y-axis shows mean change ranging from 0 to -11, and the x-axis shows treatment duration from baseline up to 13 weeks, with sample size indicated at each time point. The graph visually differentiates the three treatment groups with distinct markers and demonstrates a larger mean change over time for the 0.8 mg and 0.4 mg treatments compared to placebo.*

FDA Label Image

Ab8b786d-figure-04 (Ab8b786d Figure 04)

A line graph showing mean change over duration of treatment in weeks for Tamsulosin hydrochloride 0.8 mg, 0.4 mg, and placebo groups. The x-axis is labeled 'Duration of Treatment (weeks)' with sample sizes per timepoint, and the y-axis shows 'Mean Change' with values from 0 to -11. Three lines track the different treatment groups with markers: circles for 0.8 mg, triangles for 0.4 mg, and squares for placebo. Both Tamsulosin doses show greater mean change reduction compared to placebo over time, with data extending to 13 weeks and last observation carried forward (LOCF).*

FDA Label Image

Ab8b786d-figure-05 (Ab8b786d Figure 05)

A line graph displaying mean change in mL/sec over treatment duration in weeks for Tamsulosin hydrochloride at 0.4 mg and 0.8 mg doses compared to placebo. The graph shows trends over 13 weeks with data points labeled by sample size. The 0.4 mg and 0.8 mg treatments generally exhibit higher mean changes than placebo throughout the study period.*

FDA Label Image

Ab8b786d-figure-06 (Ab8b786d Figure 06)

A line graph depicting mean change in mL/sec over duration of treatment in weeks, comparing three groups: 0.8 mg dose, 0.4 mg dose of Tamsulosin hydrochloride, and placebo. The graph shows mean change increasing over time, with the 0.8 mg dose group exhibiting the highest mean change followed by 0.4 mg, and placebo the lowest.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.